<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00538473</url>
  </required_header>
  <id_info>
    <org_study_id>110223</org_study_id>
    <nct_id>NCT00538473</nct_id>
  </id_info>
  <brief_title>Evaluate Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults</brief_title>
  <official_title>Reactogenicity and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK576389A in Elderly Adults (≥67 Years) Previously Vaccinated With the Same Candidate Vaccine. Fluarix™ Will be Used as Reference.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      Since influenza vaccines are administered every year because of the frequent change in their
      antigenic composition, the safety and immunogenicity profile of GSK Biologicals' influenza
      vaccine GSK576389A will be re-evaluated after repeated vaccine administration. In this study,
      the subjects previously enrolled in study 107973 will receive a dose with the 2007-2008
      season's formulations of Fluarix or GSK576389A. Only subjects who were previously enrolled in
      study 107973 (NCT00386113) are eligible for participation in this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a year 3 revaccination study. Second year revaccination was done in study
      107973 (NCT00386113). First year revaccination was done in study 104540 (NCT00318058).
      Primary study was study 103304.

      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms</measure>
    <time_frame>During a 7-day follow-up period after vaccination</time_frame>
    <description>Solicited local symptoms assessed include ecchymosis, pain, redness and swelling. Any: any symptom regardless of intensity grade. Grade 3 pain: considerable pain at rest, which prevented normal everyday activities. Grade 3 ecchymosis, redness and swelling: more than 100 millimeter.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Solicited Local Symptoms</measure>
    <time_frame>During a 7-day follow-up period after vaccination</time_frame>
    <description>Duration was expressed as median number of days any symptom persisted. Solicited local symptoms assessed include ecchymosis, pain, redness and swelling. Any: occurrence of any local symptom regardless of their intensity grade.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms</measure>
    <time_frame>During a 7-day follow-up period after vaccination</time_frame>
    <description>Solicited general symptoms assessed include arthralgia, fatigue, headache, myalgia, nausea, shivering and fever. Any: any symptom regardless of intensity grade; any fever: oral temperature greater than or equal to 38 degrees Celsius (°C). Grade 3: symptoms that prevented normal activity ; Grade 3 fever: oral temperature greater than 39°C. Related: symptom assessed by the investigator as causally related to the study vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Solicited General Symptoms</measure>
    <time_frame>During a 7-day follow-up period after vaccination</time_frame>
    <description>Duration was expressed as median number of days any symptom persisted. Solicited general symptoms assessed include arthralgia, fatigue, headache, myalgia, nausea, shivering and fever. Any: occurrence of any general symptom regardless of their intensity grade or relationship to vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</measure>
    <time_frame>During a 21-day follow-up period after vaccination</time_frame>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any: occurrence of any unsolicited AE regardless of their intensity grade or relationship to vaccination. Grade 3: unsolicited AE that prevented normal everyday activities. Related: unsolicited AE assessed by the investigator as causally related to the study vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Medically Significant Conditions (MSCs)</measure>
    <time_frame>During a 21-day follow-up period after vaccination</time_frame>
    <description>Medically Significant Conditions (MSCs) included all unsolicited adverse events that resulted in a medically attended visit. Any: occurrence of any MSC regardless of their intensity grade or relationship to vaccination. Grade 3: MSC that prevented normal everyday activities. Related: MSC assessed by the investigator as causally related to the study vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)</measure>
    <time_frame>Throughout the entire study (up to Day 21)</time_frame>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any: occurrence of any SAE regardless of their relationship to vaccination. Related: SAE assessed by the investigator as causally related to the study vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Haemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Vaccine Strains</measure>
    <time_frame>At Days 0 and 21</time_frame>
    <description>Titers were expressed as Geometric Mean Titers. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seropositive for HI Antibodies Against Each of the Three Vaccine Strains</measure>
    <time_frame>At Days 0 and 21</time_frame>
    <description>A seropositive subject was defined as a subject with a serum HI titer greater than or equal to 1:10. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroconverted for HI Antibodies Against Each of the Three Vaccine Strains</measure>
    <time_frame>At Day 21</time_frame>
    <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer below1:10 and a post-vaccination titer greater than or equal to1:40 or a pre-vaccination titer greater than or equal to1:10 and at least a four-fold increase in post-vaccination titer. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Factors (SCFs) for HI Antibodies Against Each of the Three Vaccine Strains</measure>
    <time_frame>At Day 21</time_frame>
    <description>Seroconversion factor was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroprotected for HI Antibodies Against Each of the Three Vaccine Strains</measure>
    <time_frame>At Days 0 and 21</time_frame>
    <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cytokine-positive Cluster of Differentiation 4 (CD4) T Lymphocytes Per Million T Lymphocytes for Each of the Three Vaccine Strains</measure>
    <time_frame>At Days 0 and 21</time_frame>
    <description>Results are presented as geometric mean number of specific influenza CD4 T lymphocytes per million T lymphocytes. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia. Results are given for All doubles (i.e. CD4 T lymphocytes expressing at least 2 different cytokines [Cluster of Differentiation 40L (CD40L), Interleukin-2 (IL-2), Tumor Necrosis Factor alpha (TNF-α), Interferon gamma (IFN-γ)]) and for CD4 T lymphocytes expressing one particular cytokine (CD40L, IL-2, TNF-α, or IFN-γ) and least one other.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cytokine-positive Cluster of Differentiation 8 (CD8) T Lymphocytes Per Million T Lymphocytes for Each of the Three Vaccine Strains</measure>
    <time_frame>At Days 0 and 21</time_frame>
    <description>Results are presented as geometric mean number of specific influenza CD8 T lymphocytes per million T lymphocytes. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia. Results are given for All doubles (i.e. CD8 T lymphocytes expressing at least 2 different cytokines [Cluster of Differentiation 40L (CD40L), Interleukin-2 (IL-2), Tumor Necrosis Factor alpha (TNF-α), Interferon gamma (IFN-γ)]) and for CD8 T lymphocytes expressing one particular cytokine (CD40L, IL-2, TNF-α, or IFN-γ) and least one other.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>FluAS25 (GSK576389A) Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 1 dose of GlaxoSmithKline (GSK) Biologicals' AS25 adjuvanted influenza vaccine (GSK576389A).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluarix Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received 1 dose of Fluarix™.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' influenza vaccine GSK576389A</intervention_name>
    <description>Single dose, intramuscular injection</description>
    <arm_group_label>FluAS25 (GSK576389A) Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix™</intervention_name>
    <description>Single dose, intramuscular injection</description>
    <arm_group_label>Fluarix Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who were previously vaccinated with GlaxoSmithKline Biologicals Fluarix™ or
             GSK576389A vaccines in the 107973 study (NCT00386113).

          -  Subjects who the investigator believes that they can and will comply with the
             requirements of the protocol should be enrolled in the study.

          -  A male or female aged &gt;= 67 years at the time of re-vaccination.

          -  Written informed consent obtained from the subject.

          -  Free of an acute aggravation of the health status as established by clinical
             evaluation (medical history and medical history directed examination) before entering
             into the study.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccines within 30 days prior to vaccination, or planned use during the study
             period.

          -  Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or
             4 weeks (for live vaccines) prior to enrolment in this study.

          -  Planned administration of a vaccine not foreseen by the study protocol up to 21 days
             after vaccination.

          -  Confirmed influenza infection since the date of previous vaccination.

          -  Planned administration of an influenza vaccine other than the study vaccines during
             the entire study period.

          -  Vaccination against influenza since January 2007 with the Northern Hemisphere
             2007/2008 influenza vaccine or 2006/2007 influenza vaccine.

          -  Administration of more than 14 days of immunosuppressants or other immune-modifying
             drugs within six months prior to the administration of the study vaccine.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination (no laboratory testing required).

          -  History of hypersensitivity to a previous dose of influenza vaccine.

          -  History of allergy or reactions likely to be exacerbated by any component of the
             vaccine(s).

          -  Acute (active) clinically significant pulmonary, cardiovascular, hepatic or renal
             functional abnormality, as determined by clinical evaluation (medical history and
             medical history directed physical examination) or pre-existing laboratory screening
             tests.

          -  Acute disease at the time of enrolment.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the first administration of the study vaccine or planned administration
             during the study.

          -  Any medical conditions in which intramuscular injections are contraindicated.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>67 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2007</study_first_submitted>
  <study_first_submitted_qc>October 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2007</study_first_posted>
  <results_first_submitted>April 19, 2012</results_first_submitted>
  <results_first_submitted_qc>June 21, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 27, 2012</results_first_posted>
  <disposition_first_submitted>May 20, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>September 28, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 30, 2009</disposition_first_posted>
  <last_update_submitted>November 3, 2016</last_update_submitted>
  <last_update_submitted_qc>November 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK Bio's influenza vaccine GSK576389A</keyword>
  <keyword>Influenza Infection</keyword>
  <keyword>Fluarix</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>110223</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110223</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110223</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110223</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110223</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110223</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>FluAS25 (GSK576389A) Group</title>
          <description>Subjects received 1 dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A).</description>
        </group>
        <group group_id="P2">
          <title>Fluarix Group</title>
          <description>Subjects received 1 dose of Fluarix™.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FluAS25 (GSK576389A) Group</title>
          <description>Subjects received 1 dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A).</description>
        </group>
        <group group_id="B2">
          <title>Fluarix Group</title>
          <description>Subjects received 1 dose of Fluarix™.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.1" spread="4.53"/>
                    <measurement group_id="B2" value="73.2" spread="5.34"/>
                    <measurement group_id="B3" value="73.15" spread="4.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms</title>
        <description>Solicited local symptoms assessed include ecchymosis, pain, redness and swelling. Any: any symptom regardless of intensity grade. Grade 3 pain: considerable pain at rest, which prevented normal everyday activities. Grade 3 ecchymosis, redness and swelling: more than 100 millimeter.</description>
        <time_frame>During a 7-day follow-up period after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort including all subjects with the study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 (GSK576389A) Group</title>
            <description>Subjects received 1 dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects received 1 dose of Fluarix™.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms</title>
          <description>Solicited local symptoms assessed include ecchymosis, pain, redness and swelling. Any: any symptom regardless of intensity grade. Grade 3 pain: considerable pain at rest, which prevented normal everyday activities. Grade 3 ecchymosis, redness and swelling: more than 100 millimeter.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort including all subjects with the study vaccine administered.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Solicited Local Symptoms</title>
        <description>Duration was expressed as median number of days any symptom persisted. Solicited local symptoms assessed include ecchymosis, pain, redness and swelling. Any: occurrence of any local symptom regardless of their intensity grade.</description>
        <time_frame>During a 7-day follow-up period after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort on those subjects who reported the specific symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 (GSK576389A) Group</title>
            <description>Subjects received 1 dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects received 1 dose of Fluarix™.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Solicited Local Symptoms</title>
          <description>Duration was expressed as median number of days any symptom persisted. Solicited local symptoms assessed include ecchymosis, pain, redness and swelling. Any: occurrence of any local symptom regardless of their intensity grade.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort on those subjects who reported the specific symptom.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ecchymosis (N= 0; 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No subjects experienced this symptom</measurement>
                    <measurement group_id="O2" value="5.0" lower_limit="5.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (N= 17; 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness (N= 10; 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling (N= 2; 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="2.5" lower_limit="2.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms</title>
        <description>Solicited general symptoms assessed include arthralgia, fatigue, headache, myalgia, nausea, shivering and fever. Any: any symptom regardless of intensity grade; any fever: oral temperature greater than or equal to 38 degrees Celsius (°C). Grade 3: symptoms that prevented normal activity ; Grade 3 fever: oral temperature greater than 39°C. Related: symptom assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>During a 7-day follow-up period after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort including all subjects with the study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 (GSK576389A) Group</title>
            <description>Subjects received 1 dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects received 1 dose of Fluarix™.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms</title>
          <description>Solicited general symptoms assessed include arthralgia, fatigue, headache, myalgia, nausea, shivering and fever. Any: any symptom regardless of intensity grade; any fever: oral temperature greater than or equal to 38 degrees Celsius (°C). Grade 3: symptoms that prevented normal activity ; Grade 3 fever: oral temperature greater than 39°C. Related: symptom assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort including all subjects with the study vaccine administered.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Solicited General Symptoms</title>
        <description>Duration was expressed as median number of days any symptom persisted. Solicited general symptoms assessed include arthralgia, fatigue, headache, myalgia, nausea, shivering and fever. Any: occurrence of any general symptom regardless of their intensity grade or relationship to vaccination.</description>
        <time_frame>During a 7-day follow-up period after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort on those subjects who reported the specific symptom.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 (GSK576389A) Group</title>
            <description>Subjects received 1 dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects received 1 dose of Fluarix™.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Solicited General Symptoms</title>
          <description>Duration was expressed as median number of days any symptom persisted. Solicited general symptoms assessed include arthralgia, fatigue, headache, myalgia, nausea, shivering and fever. Any: occurrence of any general symptom regardless of their intensity grade or relationship to vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort on those subjects who reported the specific symptom.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Arthralgia (N= 8; 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue (N= 8; 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N= 8; 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N= 8; 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea (N= 3; 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="2.0" lower_limit="2.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering (N= 6; 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (N= 1; 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Information on duration of fever was missing from this subject’s symptom sheet.</measurement>
                    <measurement group_id="O2" value="NA">None of the subjects in this group reported fever.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any: occurrence of any unsolicited AE regardless of their intensity grade or relationship to vaccination. Grade 3: unsolicited AE that prevented normal everyday activities. Related: unsolicited AE assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>During a 21-day follow-up period after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort including all subjects with the study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 (GSK576389A) Group</title>
            <description>Subjects received 1 dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects received 1 dose of Fluarix™.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</title>
          <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any: occurrence of any unsolicited AE regardless of their intensity grade or relationship to vaccination. Grade 3: unsolicited AE that prevented normal everyday activities. Related: unsolicited AE assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort including all subjects with the study vaccine administered.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Medically Significant Conditions (MSCs)</title>
        <description>Medically Significant Conditions (MSCs) included all unsolicited adverse events that resulted in a medically attended visit. Any: occurrence of any MSC regardless of their intensity grade or relationship to vaccination. Grade 3: MSC that prevented normal everyday activities. Related: MSC assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>During a 21-day follow-up period after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort including all subjects with the study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 (GSK576389A) Group</title>
            <description>Subjects received 1 dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects received 1 dose of Fluarix™.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related Medically Significant Conditions (MSCs)</title>
          <description>Medically Significant Conditions (MSCs) included all unsolicited adverse events that resulted in a medically attended visit. Any: occurrence of any MSC regardless of their intensity grade or relationship to vaccination. Grade 3: MSC that prevented normal everyday activities. Related: MSC assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort including all subjects with the study vaccine administered.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any MSCs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 MSCs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related MSCs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any: occurrence of any SAE regardless of their relationship to vaccination. Related: SAE assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Throughout the entire study (up to Day 21)</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort including all subjects with the study vaccine administered.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 (GSK576389A) Group</title>
            <description>Subjects received 1 dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects received 1 dose of Fluarix™.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any: occurrence of any SAE regardless of their relationship to vaccination. Related: SAE assessed by the investigator as causally related to the study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort including all subjects with the study vaccine administered.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Haemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Vaccine Strains</title>
        <description>Titers were expressed as Geometric Mean Titers. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.</description>
        <time_frame>At Days 0 and 21</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity including all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 (GSK576389A) Group</title>
            <description>Subjects received 1 dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects received 1 dose of Fluarix™.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Haemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Vaccine Strains</title>
          <description>Titers were expressed as Geometric Mean Titers. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity including all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Solomon Islands [Day 0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" lower_limit="8.8" upper_limit="18.2"/>
                    <measurement group_id="O2" value="9.0" lower_limit="6.4" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [Day 21]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.0" lower_limit="41.5" upper_limit="95.7"/>
                    <measurement group_id="O2" value="42.4" lower_limit="28.3" upper_limit="63.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [Day 0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.3" lower_limit="67.2" upper_limit="149.7"/>
                    <measurement group_id="O2" value="83.1" lower_limit="63.1" upper_limit="109.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [Day 21]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252.2" lower_limit="195.8" upper_limit="324.7"/>
                    <measurement group_id="O2" value="158.4" lower_limit="114.1" upper_limit="219.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [Day 0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.8" lower_limit="37.4" upper_limit="83.3"/>
                    <measurement group_id="O2" value="61.2" lower_limit="44.2" upper_limit="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [Day 21]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.1" lower_limit="90.2" upper_limit="176.3"/>
                    <measurement group_id="O2" value="99.4" lower_limit="74.2" upper_limit="133.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seropositive for HI Antibodies Against Each of the Three Vaccine Strains</title>
        <description>A seropositive subject was defined as a subject with a serum HI titer greater than or equal to 1:10. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.</description>
        <time_frame>At Days 0 and 21</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity including all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 (GSK576389A) Group</title>
            <description>Subjects received 1 dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects received 1 dose of Fluarix™.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seropositive for HI Antibodies Against Each of the Three Vaccine Strains</title>
          <description>A seropositive subject was defined as a subject with a serum HI titer greater than or equal to 1:10. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity including all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Solomon Islands [Day 0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [Day 21]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [Day 0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [Day 21]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [Day 0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [Day 21]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroconverted for HI Antibodies Against Each of the Three Vaccine Strains</title>
        <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer below1:10 and a post-vaccination titer greater than or equal to1:40 or a pre-vaccination titer greater than or equal to1:10 and at least a four-fold increase in post-vaccination titer. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.</description>
        <time_frame>At Day 21</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity including all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 (GSK576389A) Group</title>
            <description>Subjects received 1 dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects received 1 dose of Fluarix™.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroconverted for HI Antibodies Against Each of the Three Vaccine Strains</title>
          <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer below1:10 and a post-vaccination titer greater than or equal to1:40 or a pre-vaccination titer greater than or equal to1:10 and at least a four-fold increase in post-vaccination titer. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity including all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Solomon Islands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Factors (SCFs) for HI Antibodies Against Each of the Three Vaccine Strains</title>
        <description>Seroconversion factor was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.</description>
        <time_frame>At Day 21</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity including all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 (GSK576389A) Group</title>
            <description>Subjects received 1 dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects received 1 dose of Fluarix™.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factors (SCFs) for HI Antibodies Against Each of the Three Vaccine Strains</title>
          <description>Seroconversion factor was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity including all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>fold increase</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Solomon Islands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="3.3" upper_limit="7.5"/>
                    <measurement group_id="O2" value="4.7" lower_limit="3.2" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="2.0" upper_limit="3.1"/>
                    <measurement group_id="O2" value="1.9" lower_limit="1.6" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.8" upper_limit="2.9"/>
                    <measurement group_id="O2" value="1.6" lower_limit="1.4" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroprotected for HI Antibodies Against Each of the Three Vaccine Strains</title>
        <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection.</description>
        <time_frame>At Days 0 and 21</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity including all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 (GSK576389A) Group</title>
            <description>Subjects received 1 dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects received 1 dose of Fluarix™.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Seroprotected for HI Antibodies Against Each of the Three Vaccine Strains</title>
          <description>A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity including all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Solomon Islands [Day 0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Solomon Islands [Day 21]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [Day 0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Wisconsin [Day 21]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [Day 0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Malaysia [Day 21]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cytokine-positive Cluster of Differentiation 4 (CD4) T Lymphocytes Per Million T Lymphocytes for Each of the Three Vaccine Strains</title>
        <description>Results are presented as geometric mean number of specific influenza CD4 T lymphocytes per million T lymphocytes. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia. Results are given for All doubles (i.e. CD4 T lymphocytes expressing at least 2 different cytokines [Cluster of Differentiation 40L (CD40L), Interleukin-2 (IL-2), Tumor Necrosis Factor alpha (TNF-α), Interferon gamma (IFN-γ)]) and for CD4 T lymphocytes expressing one particular cytokine (CD40L, IL-2, TNF-α, or IFN-γ) and least one other.</description>
        <time_frame>At Days 0 and 21</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity including all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 (GSK576389A) Group</title>
            <description>Subjects received 1 dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects received 1 dose of Fluarix™.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cytokine-positive Cluster of Differentiation 4 (CD4) T Lymphocytes Per Million T Lymphocytes for Each of the Three Vaccine Strains</title>
          <description>Results are presented as geometric mean number of specific influenza CD4 T lymphocytes per million T lymphocytes. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia. Results are given for All doubles (i.e. CD4 T lymphocytes expressing at least 2 different cytokines [Cluster of Differentiation 40L (CD40L), Interleukin-2 (IL-2), Tumor Necrosis Factor alpha (TNF-α), Interferon gamma (IFN-γ)]) and for CD4 T lymphocytes expressing one particular cytokine (CD40L, IL-2, TNF-α, or IFN-γ) and least one other.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity including all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>Cells per million</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Doubles A/Solomon Islands [Day 0] (N= 30; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="611.15" spread="487.68"/>
                    <measurement group_id="O2" value="353.41" spread="289.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Doubles A/Solomon Islands [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="761.22" spread="783.59"/>
                    <measurement group_id="O2" value="285.45" spread="288.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Doubles A/Wisconsin [Day 0] (N= 30; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="877.26" spread="529.44"/>
                    <measurement group_id="O2" value="476.38" spread="438.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Doubles A/Wisconsin [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="830.38" spread="652.85"/>
                    <measurement group_id="O2" value="357.12" spread="376.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Doubles B/Malaysia [Day 0] (N= 30; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="643.26" spread="382.49"/>
                    <measurement group_id="O2" value="391.89" spread="285.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Doubles B/Malaysia [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="657.31" spread="542.67"/>
                    <measurement group_id="O2" value="200.13" spread="370.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Doubles Pooled Strains [Day 0] (N= 30; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1401.41" spread="671.68"/>
                    <measurement group_id="O2" value="767.10" spread="490.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Doubles Pooled Strains [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1227.87" spread="1013.31"/>
                    <measurement group_id="O2" value="545.68" spread="480.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L A/Solomon Islands [Day 0] (N= 30; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="606.58" spread="484.99"/>
                    <measurement group_id="O2" value="341.61" spread="291.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L A/Solomon Islands [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="758.40" spread="773.73"/>
                    <measurement group_id="O2" value="279.59" spread="284.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L A/Wisconsin [Day 0] (N= 30; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="871.43" spread="512.44"/>
                    <measurement group_id="O2" value="472.33" spread="427.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L A/Wisconsin [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="829.38" spread="648.50"/>
                    <measurement group_id="O2" value="353.78" spread="377.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L B/Malaysia [Day 0] (N= 30; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="640.49" spread="370.62"/>
                    <measurement group_id="O2" value="387.23" spread="280.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L B/Malaysia [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="648.93" spread="535.97"/>
                    <measurement group_id="O2" value="188.93" spread="361.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L Pooled Strains [Day 0] (N= 30; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1388.14" spread="661.04"/>
                    <measurement group_id="O2" value="757.53" spread="489.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L Pooled Strains [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1209.75" spread="996.45"/>
                    <measurement group_id="O2" value="539.55" spread="476.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-γ A/Solomon Islands [Day 0] (N= 30; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="393.40" spread="328.18"/>
                    <measurement group_id="O2" value="180.69" spread="182.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-γ A/Solomon Islands [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="411.23" spread="509.98"/>
                    <measurement group_id="O2" value="150.29" spread="185.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-γ A/Wisconsin [Day 0] (N= 30; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="477.81" spread="299.82"/>
                    <measurement group_id="O2" value="232.70" spread="278.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-γ A/Wisconsin [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="357.56" spread="423.90"/>
                    <measurement group_id="O2" value="212.25" spread="191.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-γ B/Malaysia [Day 0] (N= 30; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="405.44" spread="279.02"/>
                    <measurement group_id="O2" value="175.13" spread="210.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-γ B/Malaysia [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="442.51" spread="384.08"/>
                    <measurement group_id="O2" value="174.94" spread="229.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-γ Pooled Strains [Day 0] (N= 30; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="824.34" spread="491.16"/>
                    <measurement group_id="O2" value="436.69" spread="307.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-γ Pooled Strains [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="840.65" spread="671.16"/>
                    <measurement group_id="O2" value="343.86" spread="315.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2 A/Solomon Islands [Day 0] (N= 30; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="550.06" spread="433.42"/>
                    <measurement group_id="O2" value="321.49" spread="258.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2 A/Solomon Islands [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="635.35" spread="631.73"/>
                    <measurement group_id="O2" value="241.86" spread="225.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2 A/Wisconsin [Day 0] (N= 30; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="738.42" spread="509.02"/>
                    <measurement group_id="O2" value="407.21" spread="381.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2 A/Wisconsin [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="682.25" spread="547.67"/>
                    <measurement group_id="O2" value="259.27" spread="313.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2 B/Malaysia [Day 0] (N= 30; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="562.01" spread="340.18"/>
                    <measurement group_id="O2" value="377.10" spread="257.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2 B/Malaysia [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="577.43" spread="470.86"/>
                    <measurement group_id="O2" value="194.20" spread="319.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2 Pooled Strains [Day 0] (N= 30; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1192.89" spread="595.71"/>
                    <measurement group_id="O2" value="720.90" spread="421.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2 Pooled Strains [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="977.48" spread="819.44"/>
                    <measurement group_id="O2" value="463.25" spread="390.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α A/Solomon Islands [Day 0] (N= 30; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270.39" spread="328.20"/>
                    <measurement group_id="O2" value="194.00" spread="169.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α A/Solomon Islands [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="371.92" spread="409.87"/>
                    <measurement group_id="O2" value="129.21" spread="163.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α A/Wisconsin [Day 0] (N= 30; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="584.58" spread="352.86"/>
                    <measurement group_id="O2" value="334.97" spread="281.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α A/Wisconsin [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="432.47" spread="428.19"/>
                    <measurement group_id="O2" value="271.33" spread="204.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α B/Malaysia [Day 0] (N= 30; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="278.06" spread="239.29"/>
                    <measurement group_id="O2" value="140.68" spread="165.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α B/Malaysia [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="299.35" spread="322.28"/>
                    <measurement group_id="O2" value="102.33" spread="205.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α Pooled Strains [Day 0] (N= 30; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="794.15" spread="504.33"/>
                    <measurement group_id="O2" value="496.30" spread="298.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α Pooled Strains [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="674.35" spread="584.50"/>
                    <measurement group_id="O2" value="251.59" spread="290.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cytokine-positive Cluster of Differentiation 8 (CD8) T Lymphocytes Per Million T Lymphocytes for Each of the Three Vaccine Strains</title>
        <description>Results are presented as geometric mean number of specific influenza CD8 T lymphocytes per million T lymphocytes. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia. Results are given for All doubles (i.e. CD8 T lymphocytes expressing at least 2 different cytokines [Cluster of Differentiation 40L (CD40L), Interleukin-2 (IL-2), Tumor Necrosis Factor alpha (TNF-α), Interferon gamma (IFN-γ)]) and for CD8 T lymphocytes expressing one particular cytokine (CD40L, IL-2, TNF-α, or IFN-γ) and least one other.</description>
        <time_frame>At Days 0 and 21</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity including all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>FluAS25 (GSK576389A) Group</title>
            <description>Subjects received 1 dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A).</description>
          </group>
          <group group_id="O2">
            <title>Fluarix Group</title>
            <description>Subjects received 1 dose of Fluarix™.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cytokine-positive Cluster of Differentiation 8 (CD8) T Lymphocytes Per Million T Lymphocytes for Each of the Three Vaccine Strains</title>
          <description>Results are presented as geometric mean number of specific influenza CD8 T lymphocytes per million T lymphocytes. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia. Results are given for All doubles (i.e. CD8 T lymphocytes expressing at least 2 different cytokines [Cluster of Differentiation 40L (CD40L), Interleukin-2 (IL-2), Tumor Necrosis Factor alpha (TNF-α), Interferon gamma (IFN-γ)]) and for CD8 T lymphocytes expressing one particular cytokine (CD40L, IL-2, TNF-α, or IFN-γ) and least one other.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity including all evaluable subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
          <units>Cells per million</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Doubles A/Solomon Islands [Day 0] (N= 30; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="54.81"/>
                    <measurement group_id="O2" value="3.01" spread="124.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Doubles A/Solomon Islands [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.18" spread="80.49"/>
                    <measurement group_id="O2" value="3.81" spread="52.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Doubles A/Wisconsin [Day 0] (N= 29; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.48" spread="87.38"/>
                    <measurement group_id="O2" value="1.55" spread="40.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Doubles A/Wisconsin [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.11" spread="95.32"/>
                    <measurement group_id="O2" value="2.49" spread="55.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Doubles B/Malaysia [Day 0] (N= 29; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.20" spread="90.23"/>
                    <measurement group_id="O2" value="2.51" spread="63.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Doubles B/Malaysia [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.26" spread="186.70"/>
                    <measurement group_id="O2" value="4.59" spread="70.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Doubles Pooled Strains [Day 0] (N= 29; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.67" spread="123.74"/>
                    <measurement group_id="O2" value="4.43" spread="75.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Doubles Pooled Strains [Day 21] (N= 24; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.96" spread="135.32"/>
                    <measurement group_id="O2" value="4.16" spread="98.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L A/Solomon Islands [Day 0] (N= 30; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" spread="27.92"/>
                    <measurement group_id="O2" value="2.38" spread="57.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L A/Solomon Islands [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" spread="52.91"/>
                    <measurement group_id="O2" value="3.17" spread="44.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L A/Wisconsin [Day 0] (N= 29; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.28" spread="60.42"/>
                    <measurement group_id="O2" value="1.55" spread="40.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L A/Wisconsin [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.14" spread="51.75"/>
                    <measurement group_id="O2" value="1.83" spread="41.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L B/Malaysia [Day 0] (N= 29; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.59" spread="77.30"/>
                    <measurement group_id="O2" value="2.03" spread="45.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L B/Malaysia [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.08" spread="75.58"/>
                    <measurement group_id="O2" value="3.67" spread="64.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L Pooled Strains [Day 0] (N= 29; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.61" spread="69.93"/>
                    <measurement group_id="O2" value="3.65" spread="58.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L Pooled Strains [Day 21] (N= 24; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.37" spread="88.95"/>
                    <measurement group_id="O2" value="2.91" spread="87.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-γ A/Solomon Islands [Day 0] (N= 30; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="25.17"/>
                    <measurement group_id="O2" value="1.60" spread="123.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-γ A/Solomon Islands [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="18.00"/>
                    <measurement group_id="O2" value="1.73" spread="23.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-γ A/Wisconsin [Day 0] (N= 29; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="58.89"/>
                    <measurement group_id="O2" value="1.52" spread="26.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-γ A/Wisconsin [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="19.53"/>
                    <measurement group_id="O2" value="1.78" spread="33.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-γ B/Malaysia [Day 0] (N= 29; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.18" spread="60.84"/>
                    <measurement group_id="O2" value="2.34" spread="63.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-γ B/Malaysia [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" spread="127.13"/>
                    <measurement group_id="O2" value="1.52" spread="22.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-γ Pooled Strains [Day 0] (N= 29; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.39" spread="93.19"/>
                    <measurement group_id="O2" value="1.53" spread="30.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-γ Pooled Strains [Day 21] (N= 24; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.24" spread="61.69"/>
                    <measurement group_id="O2" value="1.84" spread="39.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2 A/Solomon Islands [Day 0] (N= 30; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.49" spread="54.69"/>
                    <measurement group_id="O2" value="2.46" spread="66.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2 A/Solomon Islands [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.39" spread="76.84"/>
                    <measurement group_id="O2" value="3.38" spread="48.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2 A/Wisconsin [Day 0] (N= 29; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.27" spread="69.84"/>
                    <measurement group_id="O2" value="1.76" spread="41.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2 A/Wisconsin [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.63" spread="95.37"/>
                    <measurement group_id="O2" value="1.82" spread="38.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2 B/Malaysia [Day 0] (N= 29; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.86" spread="77.20"/>
                    <measurement group_id="O2" value="1.78" spread="44.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2 B/Malaysia [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.60" spread="75.43"/>
                    <measurement group_id="O2" value="3.72" spread="63.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2 Pooled Strains [Day 0] (N= 29; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.44" spread="95.70"/>
                    <measurement group_id="O2" value="6.54" spread="69.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2 Pooled Strains [Day 21] (N= 24; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.63" spread="107.41"/>
                    <measurement group_id="O2" value="3.39" spread="91.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α A/Solomon Islands [Day 0] (N= 30; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" spread="23.46"/>
                    <measurement group_id="O2" value="2.77" spread="101.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α A/Solomon Islands [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.47" spread="55.20"/>
                    <measurement group_id="O2" value="2.67" spread="36.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α A/Wisconsin [Day 0] (N= 29; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.36" spread="69.91"/>
                    <measurement group_id="O2" value="1.31" spread="18.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α A/Wisconsin [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08" spread="53.64"/>
                    <measurement group_id="O2" value="2.03" spread="32.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α B/Malaysia [Day 0] (N= 29; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.09" spread="61.50"/>
                    <measurement group_id="O2" value="3.29" spread="77.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α B/Malaysia [Day 21] (N= 25; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" spread="127.13"/>
                    <measurement group_id="O2" value="1.83" spread="34.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α Pooled Strains [Day 0] (N= 29; 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.37" spread="82.35"/>
                    <measurement group_id="O2" value="1.59" spread="50.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α Pooled Strains [Day 21] (N= 24; 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.12" spread="88.07"/>
                    <measurement group_id="O2" value="2.38" spread="37.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Events collected by systematic assessment: 7-day follow-up period after vaccination. Events collected by non-systematic assessment: 21-day follow-up period after vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>FluAS25 (GSK576389A) Group</title>
          <description>Subjects received 1 dose of GlaxoSmithKline (GSK) Biologicals’ AS25 adjuvanted influenza vaccine (GSK576389A).</description>
        </group>
        <group group_id="E2">
          <title>Fluarix Group</title>
          <description>Subjects received 1 dose of Fluarix™.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

